首页> 美国卫生研究院文献>Disease Markers >High SHIP2 Expression Indicates Poor Survival in Colorectal Cancer
【2h】

High SHIP2 Expression Indicates Poor Survival in Colorectal Cancer

机译:SHIP2高表达表明大肠癌生存率低

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

SH2-containing inositol 5′-phosphatase 2 (SHIP2), which generally regulates insulin signaling, cytoskeleton remodeling, and receptor endocytosis, has been suggested to play a significant role in tumor development and progression. However, the associations between SHIP2 expression and the clinical features to evaluate its clinicopathologic significance in colorectal cancer (CRC) have not been determined yet. In the present study, one-step quantitative real-time polymerase chain reaction (qPCR) test and immunohistochemistry (IHC) analysis with CRC tissue microarrays (TMA) were employed to evaluate the mRNA and protein expression of SHIP2 in CRC. The results showed that SHIP2 expression in the mRNA and protein levels was significantly higher in CRC tissues than that in corresponding noncancerous tissues (both P < 0.05). The expression of SHIP2 protein in CRC was related to lymph node metastasis (P = 0.036), distant metastasis (P = 0.001), and overall survival (P = 0.009). Kaplan-Meier method and Cox multifactor analysis suggested that high SHIP2 protein level (P = 0.040) and positive distant metastasis (P = 0.048) were critically associated with the unfavorable survival of CRC patients. The findings suggested that SHIP2 may be identified as a useful prognostic marker in CRC and targeting CRC may provide novel strategy for CRC treatment.
机译:含SH2的肌醇5'-磷酸酶2(SHIP2)通常调节胰岛素信号传导,细胞骨架重塑和受体胞吞作用,已被认为在肿瘤的发展和进程中起着重要的作用。然而,尚未确定SHIP2表达与临床特征之间的关联以评估其在结直肠癌(CRC)中的临床病理学意义。在本研究中,采用CRC组织微阵列(TMA)的一步定量实时聚合酶链反应(qPCR)测试和免疫组织化学(IHC)分析来评估SHIP2在CRC中的mRNA和蛋白表达。结果显示,在CRC组织中,SHIP2在mRNA和蛋白水平中的表达明显高于相应的非癌性组织(两者均P <0.05)。 CRC中SHIP2蛋白的表达与淋巴结转移(P = 0.036),远处转移(P = 0.001)和总生存期(P = 0.009)有关。 Kaplan-Meier方法和Cox多因素分析表明,SHIP2蛋白水平高(P = 0.040)和远处转移阳性(P = 0.048)与CRC患者的不良生存率密切相关。这些发现表明,SHIP2可能被认为是CRC中有用的预后标志物,靶向CRC可能为CRC治疗提供新的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号